Source comparison
Melanotan-1 Photoprotection: Clinical Applications Comparison
Erythropoietic Protoporphyria (EPP) 3–6 mJ/cm² 6–12× increase (18–69 mJ/cm²) 60-day implant or 21–28 days subcutaneous Severe photosensitivity causing phototoxic pain within minutes of sun exposure First-line peptide therapy for EPP patients. FDA and EMA appro
This comparison does not assign a generated winner or score.
- Erythropoietic Protoporphyria (EPP)
- 3–6 mJ/cm²
- 6–12× increase (18–69 mJ/cm²)
- 60-day implant or 21–28 days subcutaneous
- Severe photosensitivity causing phototoxic pain within minutes of sun exposure
- First-line peptide therapy for EPP patients. FDA and EMA approved. MED improvements allow outdoor activity that was previously intolerable.
- Fitzpatrick Type I–II Recreational Use
- 20–30 mJ/cm²
- 2–4× increase (40–120 mJ/cm²)
- 21–28 days before sun exposure, maintenance dosing during trip
- Prevention of sunburn during vacations or outdoor events in high UV environments
- Off-label use. Provides measurable photoprotection but does not replace sunscreen. Best combined with SPF 30+ and protective clothing.
- Polymorphous Light Eruption (PMLE)
- 15–25 mJ/cm²
- 2–3× increase (30–75 mJ/cm²)
- 14–21 days before expected UV exposure
- Photodermatosis causing pruritic papules and plaques after sun exposure
- Effective for PMLE prophylaxis in patients unresponsive to topical corticosteroids. Melanin accumulation reduces inflammatory cascade triggered by UVA.
- Vitiligo Repigmentation (Off-Label)
- Variable. Depigmented areas have 0 MED
- Modest repigmentation in 30–40% of patients
- 90–120 days minimum
- Autoimmune depigmentation disorder affecting melanocyte function
- Limited efficacy as monotherapy. MC1R agonism cannot restore melanocytes destroyed by autoimmune attack. Combination with narrowband UVB shows better outcomes.
- Seasonal Affective Disorder (Investigational)
- N/A
- 28 days
- Mood disorder linked to reduced sunlight exposure in winter months
- Mechanism unrelated to photoprotection. MC4R activation may influence mood pathways, but melanotan-1 has minimal MC4R affinity. Melanotan-2 shows stronger preliminary signals.